First report on the enhancement of CD3AK cell proliferation and killing activity by α-Thujone.
α-Thujone increases the expression of CD107a, p-Akt and p-ERK1/2.
Our findings provided that α-Thujone combined CD3AK cells in the treatment of colon cancer.